Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Vam	e of entity		ABN/ARSN
Sig	ma Pharmaceuticals Limited	15 088 417 403	
We	(the entity) give ASX the following	ng information.	
ní	formation about buy-back		
	Type of buy-back	On-market buy-back	
	Date Appendix 3C was given to ASX	13 September 2012 (Associated Appendi	x 3D dated 4 Oct
		2013)	X 05 dated 1 00t
	tal of all shares/units be ceptances have been recei	ought back, or in ved, before, and on Before previous	relation to wh
		ought back, or in ved, before, and on	relation to whi
		ought back, or in ved, before, and on Before previous	relation to wh , previous day

Before previous	Previous day
day	

5 If buy-back is an on-market buy-back

Highest \$0.8525	price	paid:	Highest price paid: \$0.6250
Lowest	prioc	noid	Lowest price paid: \$0.6200
\$0.5600	price	paid:	Highest price allowed under rule 7.33: \$0.6258

How many shares/units may still be bought back?

6 If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back

52,401,075			

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:

Date: 17 December 2013

(Director/Company secretary)

Print name: SUE MORGAN

== == == ==